Biomarker based diagnostics have already offered great advanced in the past decade in the field of cancer diagnosis, prognosis, staging and therapy selection. However, tissue-based detection approach produces a major drawback in terms of invasion for sample collection. Over the last few years, several cancer biomarker research studies have moved their focus on analysis of biomarkers found in biological fluids, which offer minimal invasion and longer disease tracking - liquid biopsy. Several cancer diagnostic companies and startups have accepted the challenge of commercializing liquid biopsy tools in the market.

For the purpose of this study, the liquid biopsy market is studied by analytes and applications. Based on analytes, this report studies circulating tumor cells (CTCs) circulating tumor DNA (ctDNA) and extracellular vesicles (SVs) segments. Liquid biopsy techniques find application in cancer prognosis, diagnosis and therapy monitoring. This report provides market size and forecast (USD Mn) for such considered segments for the period 2014-2023, along with their respective CAGRs (value %) for the period 2016-2023, considering 2015 as the base year.

Geographically, the global liquid biopsy market is categorized into the following regional markets:

The market size and forecast for the period 2014-2023 along with the CAGRs for the period 2016-2023 for the mentioned segments are also presented in this study.

This study also provides qualitative assessment tools for the readers that offer the overall status and trends in the liquid biopsy market. Such sections include market dynamics (drivers, challenges, future prospects), major commercial events, and major research events. For competitive assessment, tools such as attractive investment proposition and fractal map analysis (by key market players) are also presented in this study. This report concludes with company profiles section that highlights major information about key companies operating in the liquid biopsy market. Some of the major market players covered in this section include Myriad Genetics, Qiagen, Trovagene, Natera, Foundation Medicine, and others. The key information provided on these players is based on parameters such as business description, financial health, product portfolio, and news coverage.

Among the mentioned analyte types, CTCs demonstrate the longest history of being subject for liquid biopsy. CTC based technologies have been in practice for over a decade and their IVD use has FDA approval. ctDNA is a more recent entrant in the liquid biopsy market and is rapidly becoming an alternative to CTC assays. EVs, furthermore, is the latest addition to the liquid biopsy portfolio and is the least developed so far. Approximately a third of the overall liquid biopsy researches are concentrated on EVs development. EVs represent a set of source of circulating biomarkers in lipid coat encapsulation. The biomarkers cargo associated with EVs include exosomes, microvesicles, apoptopic bodies, large oncosomes and others.

Liquid biopsy has the potential to assist clinicians in determining cancer prognosis, stratification of patients to determine the best possible treatment modality and also assess resistance mechanisms of tumors. Molecular characterization of tumor is facilitated through liquid biopsy and its non-invasive nature paves way for repeated sampling to scrutinize genetic changes during any period, by avoiding tissue biopsy. Disease prognosis currently takes the highest share in the liquid biopsy applications market, whereas diagnostics and therapy monitoring closely compete with each other. Liquid biopsy can efficiently monitor the effectiveness of treatment regimen thus facilitate treatment optimization, and possible alterations. As the nature of tumors change over time, liquid biopsy offers the benefit of analyzing such dynamics and provide information for possible treatment change. In cases where particular genotypes are identified in patients, liquid biopsy allows early detection of cancer before the occurrence of overt symptoms.

North America is the current geographical leader in the liquid biopsy market. High demand for latest diagnostic modules, coupled with greater awareness between both patients and caregivers play a vital growth in the dominance of this region. Additionally, several giant market players and new startups operating in this market are domiciled in North America and Europe, thus allowing early bird advantage to these regions. Large number of research activities being conducted in the region also is a prime phenomenon in North America and Europe markets. However, challenged reimbursements may hold back the growth of this market to a certain extent. Introduction of cost effective solutions and rapid approvals in Latin America and Asia-Pacific will serve as the prime growth drivers in these regions.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Liquid Biopsy market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Liquid Biopsy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Liquid Biopsy market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Liquid Biopsy market?
• Which is the largest regional market for Liquid Biopsy market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Liquid Biopsy market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Liquid Biopsy market worldwide?